CRDF

Rating neutralAI MemoPost-earnings T+1

Cardiff Oncology

As of 2026-10-30/Post-earnings T+1/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

low

Horizon

—

Key catalyst

Confirm Q3 results and updated cash runway • 2026-11-30

Base target: $1 / p=45% prob

Biggest risk

The Phase 3 start depends on new capital. The June 10-Q disclosed substantial doubt about Cardiff's ability to continue as a going concern, and clinical confirmation remains uncertain [#SEC-10Q-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344545/crdf-20260630.htm). A Q3 earnings surprise or guidance revision cannot be assessed because a new company results release was not verified.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Cardiff's Phase 2 response-rate signal and FDA-aligned Phase 3 design support upside if it secures financing on acceptable terms and confirms benefit in a registrational trial [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). The September Nerviano settlement also addressed a prior license dispute, although the amended agreement carries milestone and other payment obligations (https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm).

Research note

Recommendation

neutral

Confidence

low

As of

2026-10-30

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Validate onvansertib's Phase 2 signal in a registrational trial
Cardiff's Phase 2 response-rate signal and FDA-aligned Phase 3 design support upside if it secures financing on acceptable terms and confirms benefit in a registrational trial [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm).
The September Nerviano settlement also addressed a prior license dispute, although the amended agreement carries milestone and other payment obligations (https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm).

BearKey bullets

No October 29 Q3 company earnings release or earnings 8-K was found in the checked company release and SEC filing lists; reported Q3 revenue, EPS, guidance, and consensus surprise are unavailable (https://investors.cardiffoncology.com/news-events/press-releases; https://investors.cardiffoncology.com/financial-information/sec-filings).
Phase 2 progression-free-survival estimates had wide confidence intervals; later-stage efficacy, safety, enrollment, and regulatory success are not assured [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm).
The June 10-Q disclosed going-concern uncertainty, a need for additional financing, and possible shareholder dilution [#SEC-10Q-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344545/crdf-20260630.htm).

WatchKey bullets

Confirm Q3 results and updated cash runway

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $1 (p=45%)

Target spread vs base: +76% / -47%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

The October 29 close of $0.912 was approximately 1.6% above October 28, but without a verified Q3 release it cannot be characterized as a post-earnings reaction (https://www.investing.com/equities/trovagene-inc-historical-data). No credible post-print analyst target or estimate revisions were verified. The scheduled earnings trigger therefore increases monitoring urgency, not confidence in a new operating thesis. Social coverage is unavailable.

As of 2026-10-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Validate onvansertib's Phase 2 signal in a registrational trial

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-10-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-30
Confirm Q3 results and updated cash runway
The October 29 earnings trigger is a scheduled follow-up, not a verified release. Cardiff's latest confirmed earnings exhibit reported $34.5 million in June 30 cash and investments, $24.1 million of first-half operating cash use, and a planned Phase 3 start conditional on additional financing [#SEC-8K-2026-08-11] [#10-Q-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). A Q3 release and updated runway remain to be confirmed.
Prob 70.00% • Move -8.00% • Priced-in 30.00%
EVENT2027-03-31
Secure financing for planned Phase 3 initiation
Cardiff planned to initiate the onvansertib Phase 3 trial in first-quarter 2027, explicitly subject to additional financing [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). Financing terms and the resulting dilution could dominate the near-term equity outcome; the October filing increased authorized common shares to 300 million [#8-K-2026-10-27] (https://www.sec.gov/Archives/edgar/data/1213037/000149315226048720/form8-k.htm).
Prob 55.00% • Move -15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Validate onvansertib's Phase 2 signal in a registrational trial
2028-12-31
The selected 30 mg onvansertib plus FOLFIRI/bevacizumab arm showed a 72.2% confirmed response rate versus 42.1% for the control arm in the company's Phase 2 update, but the reported progression-free-survival confidence interval was wide [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). Phase 3 execution and eventual confirmatory data—not a dated near-term readout—are the longer-term valuation test.
Prob 40% • Move 45% • Priced-in 25%

Risks

No October 29 Q3 company earnings release or earnings 8-K was found in the checked company release and SEC filing lists; reported Q3 revenue, EPS, guidance, and consensus surprise are unavailable (https://investors.cardiffoncology.com/news-events/press-releases; https://investors.cardiffoncology.com/financial-information/sec-filings).
Phase 2 progression-free-survival estimates had wide confidence intervals; later-stage efficacy, safety, enrollment, and regulatory success are not assured [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm).
The June 10-Q disclosed going-concern uncertainty, a need for additional financing, and possible shareholder dilution [#SEC-10Q-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344545/crdf-20260630.htm).
The October 27 filing disclosed a chief-medical-officer transition and an increase in authorized common shares, adding execution and dilution considerations [#8-K-2026-10-27] (https://www.sec.gov/Archives/edgar/data/1213037/000149315226048720/form8-k.htm).

Peers

Symbol	Summary
CGTX	Similar-size clinical-stage biotech screening comparator only; the packet does not establish comparable indication, mechanism, or trial economics.
NMRA	Broad clinical-stage biotech comparator; not a validated onvansertib or colorectal-cancer valuation peer.
TENX	Similar-market-cap biotech comparator only; direct clinical and funding comparability is unverified.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-30

Loading AI feed…

Symbol

Summary

CGTX

Similar-size clinical-stage biotech screening comparator only; the packet does not establish comparable indication, mechanism, or trial economics.

NMRA

Broad clinical-stage biotech comparator; not a validated onvansertib or colorectal-cancer valuation peer.

TENX

Similar-market-cap biotech comparator only; direct clinical and funding comparability is unverified.